Zusammenfassung
Hintergrund: Die Bedeutung thrombophiler Gerinnungsstörungen für die Entstehung venöser retinaler
Gefäßverschlüsse wird immer noch kontrovers diskutiert. Patienten und Methoden: In einer prospektiven Fall-Kontroll-Studie untersuchten wir 74 junge Patienten (≤
45 Jahre zum Zeitpunkt des retinalen Gefäßverschlusses oder eines früheren thromboembolischen
Ereignisses) mit retinalem Zentral-, Hemizentral- oder Astvenenverschluss und 74 gesunde
Probanden auf thrombophile Gerinnungsstörungen und kardiovaskuläre Risikofaktoren.
Ergebnisse: 38 der 74 Patienten (51,4 %) wiesen thrombophile Gerinnungsstörungen auf, während
lediglich bei 8 der 74 Probanden Koagulopathien aufgedeckt werden konnten (p < 0,0001).
Darüber hinaus konnten wir thrombophile Gerinnungsstörungen signifikant häufig bei
Patienten mit einer auffälligen Familienanamnese hinsichtlich thromboembolischer Komplikationen
(p < 0,0001) und bei Patienten ohne kardiovaskuläre Risikofaktoren nachweisen (p
= 0,0025). Schlussfolgerung: Unsere Ergebnisse weisen daraufhin, dass Gerinnungsstörungen neben kardiovaskulären
Risikofaktoren bei jungen Patienten mit venösen retinalen Gefäßverschlüssen eine pathogenetische
Bedeutung zukommt. Eine positive Eigen- oder Familienanamnese hinsichtlich thromboembolischer
Ereignisse sowie das Fehlen kardiovaskulärer Risikofaktoren weisen signifikant häufig
auf eine zugrunde liegende Thrombophilie hin.
Abstract
Background: The potential impact of coagulation abnormalities on retinal vascular occlusive diseases,
individually and in combination with cardiovascular risk factors, remains unclear.
Patients and Methods: In a prospective case-control study a cohort of 74 young patients with central, hemicentral
or branch retinal vein occlusion (RVO) (≤ 45 years at the time of the RVO or a previous
thromboembolic event) and 74 subjects matched for age and sex were prospectively screened
for thrombophilic risk factors. Results: Overall, thrombophilic defects were found to be present in 38 of the 74 patients
(51.4 %) and in 8 of 74 (10.8 %) controls (p < 0.0001). We found a strong association
between the presence of thrombophilic disorders and a family history of thromboembolism
(p < 0.0001). Patients without cardiovascular risk factors had a statistically significant
higher frequency of coagulation disorders than patients with these risk factors (p
= 0.0025). Conclusions: Our results indicate that thrombophilic disorders are associated with the development
of retinal vein occlusion. Selective screening of young patients, patients with a
personal or family history of thromboembolism, and patients without cardiovascular
risk factors may be helpful in identifying retinal vein occlusion patients with thrombophilic
defects.
Schlüsselwörter
Thrombophilie - APC-Resistenz - Antiphospholipidantikörper - retinale venöse Gefäßverschlüsse
Key words
thrombophilia - resistance to APC - antiphospholipid antibodies - retinal vein occlusion
Literatur
1
Abu el-Asrar A M, al-Momen A K, al-Amro S. et al .
Prothrombotic states associated with retinal venous occlusion in young adults.
Int Ophthalmol.
1996 – 1997;
20
197-204
2
Arséne S, Delahousse B, Regina S. et al .
Increased prevalence of factor V Leiden in patients with retinal vein occlusion and
under 60 years of age.
Thromb Haemost.
2005;
94
101-106
3
Ates O.
The deficiencies of protein C, protein S and antithrombin III in patients with retinal
vein occlusion: a Turkish sample.
Clin Lab Haematol.
2006;
28
391-392
4
Cushman M.
Inherited Risk Factors for Venous Thrombosis.
Hematology Am Soc Hematol Educ Program.
2005;
452-457
5
De Stefano V, Rossi E, Paciaroni K. et al .
Screening for inherited thrombophilia: indications and therapeutic implications.
Haematologica.
2002;
87
1095-1108
6
Dori D, Beiran I, Gelfand Y. et al .
Multiple retinal arteriolar occlusions associated with coexisting primary antiphospholipid
syndrome and factor V Leiden mutation.
Am J Ophthalmol.
2000;
129
106-108
7
Glueck C J, Bell H, Vadlamani L. et al .
Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion.
Arch Ophthalmol.
1999;
117
43-49
8
Gottlieb J L, Blice J P, Mestichelli B. et al .
Activated Protein C Resistance, Factor V Leiden, and Central Retinal Vein Occlusion
in Young Adults.
Arch Ophthalmol.
1998;
116
577-579
9
Graham S L, Goldberg I, Murray B. et al .
Activated protein C resistance – low incidence in glaucomatous optic disc haemorrhage
and central retinal vein occlusion.
Aust NZ J Ophthalmol.
1996;
24
199-205
10
Green W R, Chan C C, Hutchins G M. et al .
Central retinal vein occlusion: a prospective histopthalogic study of 29 eyes in 28
cases.
Trans Am Ophthalmol Soc.
1981;
79
371-422
11
Greiner K, Hafner G, Dick B. et al .
Retinal Vascular Occlusion and Deficiencies in the Protein C Pathway.
Am J Ophthalmol.
1999;
128
69-74
12
Hattenbach L O, Klais C, Scharrer I.
Heparin cofactor II deficiency in central retinal vein occlusion.
Acta Ophthalmol Scand.
1998;
76
758-759
13
Kearon C, Ginsberg J S, Kovacs M J. et al .
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin
therapy for long-term prevention of recurrent venous thromboembolism.
N Engl J Med.
2003;
349
631-639
14
Krüger K, Witt I.
Inhibitors of blood coagulation in vascular occlusion of the retina and optic nerve.
Fortschr Ophthalmol.
1990;
78
178-181
15
Kuhli C, Hattenbach L O, Scharrer I. et al .
High Prevalence of resistance to APC in young patients with retinal vein occlusion.
Graefe’s Arch Clin Exp Ophthalmol.
2002;
240
163-168
16
Kuhli C, Scharrer I, Koch F. et al .
Recurrent retinal vein occlusion in a patient with increased plasma levels of histidine-rich
glycoprotein.
Am J Ophthalmol.
2003;
135
232-234
17
Lahey J M, Tunc M, Kearnea J. et al .
Laboratory evaluation of Hypercoagulable states in patients with central retinal vein
occlusion who are less than 56 years of age.
Ophthalmology.
2002;
109
126-131
18
Lane D A, Manucci P M, Bauer K A. et al .
Inherited thrombophila: Part 1.
Thromb Haemost.
1996;
75
651-662
19
Larsson J, Olafsdottir E, Bauer B.
Activated protein C resistance in young adults with central retinal vein occlusion.
Br J Ophthalmol.
1996;
80
200-202
20
Laurell C B.
Elektroimmuno Assay.
Scand J Clin Lab Invest.
1972;
124
21-37
21
The Eye Disease Case-Control Study Group .
Risk factors for branch retinal vein occlusion.
Am J Ophthalmol.
1993;
116
286-296
22
The Eye Disease Case-Control Study Group .
Risk factors for central retinal vein occlusion.
Arch Ophthalmol.
1996;
114
545-554
23
Salomon O, Moissiev J, Rosenberg N. et al .
Analysis of genetic polymorphisms related to thrombosis and other risk factors in
patients with retinal vascular occlusion.
Blood Coagul Fibrinolysis.
1998;
9
617-622
24
Schulman S, Granqvist S, Holmström M. et al .
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.
N Engl J Med.
1997;
336
393-398
25
Scott J A, Arnold J J, Currie J M. et al .
No Excess of Factor V: Q 506 Genotype but High Prevalence of Anticardiolipin Antibodies
without Antiendothelial Cell Antibodies in Retinal Vein Occlusion in Young Patients.
Ophthalmologica.
2001;
215
217-221
26
Vine A K.
Retinal vascular occlusion and deficiencies in the protein C pathway.
Am J Ophthalmol.
2000;
129
113-115
27
Vine A K, Samama M M.
The role of abnormalities in the anticoagulant and fibrinolytic systems in retinal
vascular occlusions.
Surv Ophthalmol.
1993;
37
283-292
28
Vossen C Y, Walker I D, Svensson P. et al .
Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia.
Arterioscler Thromb Vasc Biol.
2005;
25
1992-1997
29
Weger M, Stanger O, Deutschemann H. et al .
Hyperhomocyst(e)inemia, but not methylenetetetrahydrofolate reductase C 677T mutation,
is a risk factor in branch retinal vein occlusion.
Ophthalmology.
2002;
109
1105-1109
30
Williamson T H, Rumley A, Lowe G DO.
Blood viscosity, coagulation, and activated protein C Resistance in central retinal
vein occlusion: a population controlled study.
Br J Ophthalmol.
1996;
80
203-208
31
Wu O, Robertson L, Twaddle S. et al .
The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.
Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness
analysis.
Br J Haematol.
2005;
131
80-90
Dr. Claudia Kuhli-Hattenbach
Klinik für Augenheilkunde, Universitätsklinikum
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Phone: + + 49/69/63 01 57 21
Fax: + + 49/69/63 01 77 95
Email: kuhli@med.uni-frankfurt.de